Clonazolam

Clonazolam
Clinical data
Dependence
liability		Very high
Routes of
administration		Oral
Legal status
Legal status
  • AU: Unscheduled
  • BR: Class B1 (Psychoactive drugs)
  • CA: Unscheduled
  • DE: NpSG (Industrial and scientific use only)
  • UK: Class C
  • US: Schedule I
  • UN: Schedule IV
Identifiers
  • 6-(2-Chlorophenyl)-1-methyl-8-nitro-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC17H12ClN5O2
Molar mass353.77 g·mol−1
3D model (JSmol)
  • CC1=NN=C2N1C3=C(C=C(C=C3)[N+](=O)[O-])C(=NC2)C4=CC=CC=C4Cl
  • InChI=1S/C17H12ClN5O2/c1-10-20-21-16-9-19-17(12-4-2-3-5-14(12)18)13-8-11(23(24)25)6-7-15(13)22(10)16/h2-8H,9H2,1H3
  • Key:XJRGLCAWBRZUFC-UHFFFAOYSA-N

Clonazolam (also known as clonitrazolam) is a drug of the triazolobenzodiazepine (TBZD) class, which are benzodiazepines (BZDs) fused with a triazole ring. Although little research has been done about its effects and metabolism, it is sold online as a designer drug.

The synthesis of clonazolam was first reported in 1971 and the drug was described as the most active compound in the series tested.

Depending on dose consumed, clonazolam may pose comparatively higher risk than other designer benzodiazepines due to its ability to produce strong sedation and amnesia at doses as small as 0.5 mg.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.